Dr. Stearns is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5255 Loughboro Rd NW
Washington, DC 20016Phone+1 202-537-4686
Summary
- Dr. Vered Stearns is an oncologist in New York. She received her medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice 25 years. She also speaks multiple languages, including Hebrew. She specializes in breast cancer and hematologic oncology and is experienced in breast cancer treatment and translational research. She has more than 100 publications and over 500 citings.
Education & Training
- Georgetown University HospitalFellowship, Medical Oncology, 1995 - 1997
- MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1992 - 1995
- Rutgers Robert Wood Johnson Medical SchoolClass of 1992
Certifications & Licensure
- FL State Medical License 2021 - Present
- MD State Medical License 2002 - 2025
- NY State Medical License 2023 - 2025
- DC State Medical License 1996 - 2024
- MI State Medical License 2001 - 2005
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer Start of enrollment: 1997 Mar 01
- Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer Start of enrollment: 2003 Aug 11
- Aromatase Inhibitor Clinical Trial Start of enrollment: 2005 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108.Vered Stearns, Anne ONeill, Bryan P Schneider, Todd C Skaar, Minetta C Liu
Breast Cancer Research and Treatment. 2024-10-21 - 3 citationsFactors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancer.Anna-Carson Rimer Uhelski, Amanda L Blackford, Jennifer Y Sheng, Claire Snyder, Jennifer Lehman
Journal of Cancer Survivorship. 2024-10-01 - Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion.Maria Fatteh, Jaime Wehr, Katerina Karaindrou, Rena R Xian, Christopher Gocke
JCO Precision Oncology. 2024-10-01
Press Mentions
- Behind the Study: Weight Loss Strategies for Breast Cancer SurvivorsMarch 3rd, 2022
- Battling Breast Cancer Year-Round: Why Breast Cancer Awareness Should Continue Even After OctoberOctober 30th, 2021
- Inhibitor Drug Entinostat ‘Primes’ the Body to Better Respond to Anti-Cancer Treatment with ImmunotherapyAugust 19th, 2021
- Join now to see all
Grant Support
- The Effects Of 24 Months Of Exemestane Or Letrozole On Surrogate MarkersNational Center For Research Resources2007
Professional Memberships
- Member
Other Languages
- Hebrew
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/vered-stearns
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: